BMY
Bristol-Myers Squibb·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
FDA Approved
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BMY
Bristol-Myers Squibb Company
A global biopharmaceutical company that develops and commercializes innovative medicines for serious diseases
Route 206 & Province Line Road, Princeton, New Jersey 08543
Biopharmaceuticals and Sales
Bristol-Myers Squibb Company was incorporated under the laws of Delaware in August 1933 as Bristol-Myers Corporation, inheriting a business founded in New York in 1887. In 1989, due to the merger, the company changed its name to Bristol-Myers Squibb Company. The company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global scale. The company expects the acquisition of Celgene and MyoKardia to further position the company as a leading biopharmaceutical company, expanding its portfolio in oncology, hematology, immunology and cardiovascular with several recent assets and additional external partnerships.
Earnings Call
Q1/2025
Estimate EPS1.5
Actual EPS1.8
Estimate Revenue10.71B
Actual Revenue11.20B
Cobenfy's Market Position and Trial Impact: Contradictions Unveiled in 2025 Q1 Earnings Call
May 02,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.13
Actual EPS1.46
Estimate Revenue11.38B
Actual Revenue12.27B
Bristol-Myers Squibb's Q2 2025 Earnings Call: Unpacking Contradictions in Cobenfy's Strategy and Market Dynamics
Jul 31,2025 04:49
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS1.52
Actual EPS1.63
Estimate Revenue11.80B
Actual Revenue12.20B
Bristol-Myers Squibb's Q3 2025 Earnings Call: Contradictions Emerge on Cobenfy Adoption, ADEPT-2 Delays, Reimbursement Speed, Iberdomide's MRD Endpoint, and US Manufacturing/Tariff Strategy
Oct 30,2025 04:19
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BMY has released its 2025 Q3 earnings. EPS was reported at 1.63, versus the expected 1.52, beating expectations. The chart below visualizes how BMY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BMY has released its 2025 Q3 earnings report, with revenue of 12.22B, reflecting a YoY change of 2.77%, and net profit of 2.19B, showing a YoY change of 80.66%. The Sankey diagram below clearly presents BMY's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
